Amolimogene bepiplasmid

DB04904InvestigationalVaccines

Amolimogene is an investigational therapeutic designed to specifically augment the body's defensive response to human papillomavirus (HPV). Amolimogene was biologically engineered as a targeted therapy for the treatment of cervical...

Mechanism
Curator reviewed
Primary indication
Intended for the treatment of cervical dysplasia associated with the human papillomavirus (HPV).Curator reviewed
Also known as
Amolimogene
Code names
ZYC 101a

Resolves to

What you can answer from here — as of October 28, 2025

1Clinical trialPhase, status and sponsor resolved per trial
Sign in
2+ReferencesStructured and connected to the statements they support
Sign in

Which companies are running trials of Amolimogene bepiplasmid, in which indications and phases, and which of those programs are still active?

Create a free account or log in to explore the full data card.

Create Account